Dowling & Yahnke’s Catheter Precision VTAK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
– Sell
-7
Closed -$21K – 387
2022
Q2
$21K Hold
7
– – ﹤0.01% 372
2022
Q1
$27K Hold
7
– – ﹤0.01% 373
2021
Q4
$107K Hold
7
– – 0.01% 371
2021
Q3
$215K Hold
7
– – 0.01% 351
2021
Q2
$299K Hold
7
– – 0.02% 308
2021
Q1
$319K Buy
+7
New +$458K 0.02% 287
2020
Q1
– Hold
0
– -$41K – 384
2019
Q4
– Hold
0
– – – 324
2019
Q3
– Hold
0
– – – 302
2019
Q2
– Hold
0
– – – 292

Other funds holding VTAK

Dowling & Yahnke's VTAK Position: Q3 2022 in Review

Dowling & Yahnke sold out of Catheter Precision (VTAK) in Q3 2022, closing a stake of 7 shares — an estimated $21K sold.

Dowling & Yahnke first reported a position in VTAK in Q1 2021 and held it in 6 quarters. The position peaked at $319K in Q1 2021. 17 funds tracked by Wall St. Rank hold VTAK as of Q3 2022.

  • Dowling & Yahnke reported no remaining Catheter Precision position as of Q3 2022 after selling out during the quarter.
  • Dowling & Yahnke sold 7 Catheter Precision shares in Q3 2022, an estimated $21K.
  • Dowling & Yahnke first reported a position in Catheter Precision in Q1 2021 and held it in 6 quarters.
  • Dowling & Yahnke's Catheter Precision position peaked at $319K in Q1 2021.
  • 17 funds tracked by Wall St. Rank held Catheter Precision as of Q3 2022.

Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.